PLEASANTON, Calif.--(BUSINESS WIRE)--ZELTIQ® Aesthetics, Inc. (NASDAQ: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, announced today that the underwriters of its initial public offering have exercised their option to purchase 1,050,000 shares of common stock from ZELTIQ to cover over-allotments. The sale of additional shares is expected to close on Oct 24, 2011.
J.P. Morgan Securities LLC and Goldman, Sachs & Co. acted as joint book-running managers. William Blair & Company, LLC and Canaccord Genuity Inc. acted as co-managers.
The Company has filed a registration statement, including a prospectus, with the Securities and Exchange Commission, or the SEC, for the offering to which this communication relates. Before you invest, you should read the prospectus in the registration statement and other documents ZELTIQ has filed with the SEC for more complete information about ZELTIQ and this offering. You may obtain these documents for free by visiting the SEC website at www.sec.gov. Alternatively, ZELTIQ, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by contacting: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Ave., Edgewood, NY 11717 (Tel: 866-803-9204) or Goldman, Sachs & Co., Attn: Prospectus Department, 200 West Street, New York, NY 10282, (Tel: 866-471-2526), Email: prospectus-ny@ny.email.gs.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About ZELTIQ® Aesthetics, Inc.
ZELTIQ® Aesthetics, Inc. is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. The Company’s first commercial product, the CoolSculpting® System, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise.